Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PROK vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PROK Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

PROK Overall Winner 6-Pillar Tally: PROK 4 – 1 CVM (1 Tie) Matrix Metrics: PROK 5 – 4 CVM

As of Nov 16, 2026, ProKidney Corp. Class A (PROK) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PROK carries a Unified Composite Score of 64.1/100 (BUY) at $1.02 (N/M Forward P/E, -24830.3% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.4); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PROK vs CVM
PROK NASDAQ Head-to-Head Winner
ProKidney Corp. Class A Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.02
-1.91% 1D
Market Cap $415.2M
TTM Revenue $775,000
Forward P/E N/M
Beta / 30D Vol 1.71β · 92% Vol
Unified Composite Score
64.1 / 100 BUY
Tech 76.0 Fund 52.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 35
RSI-14: 35.4 · SMA20: $1.25 · SMA50: $1.51
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (PROK 4 – 1 CVM)

Columns: Metric · PROK · CVM
1. Valuation Multiples CVM
Forward P/E N/M 23.0x
Trailing P/E N/M 23.0x
PEG Ratio N/M 1.12x
EV / Revenue N/M N/M
2. Growth & Scale PROK
Revenue Growth (YoY) -19.8% -62.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $775,000 $28,558
Market Cap $415.2M $20.9M
3. Profitability & Quality PROK
Gross Margin 100.0% N/A
Operating Margin -24830.3% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -73.4% -252.5%
4. Balance Sheet & Cash Flow PROK
Cash Generation (TTM) -$160M -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage $71M Net Cash $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PROK
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 364.9% (42nd %ile) N/A (N/A)
Put/Call OI Skew 0.83x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PROK (5) vs CVM (4)
Institutional Metric PROK CVM Criterion Row Edge
Market Capitalization
Scale
$415.2M $20.9M Larger Scale PROK
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Forward P/E Ratio
Valuation
N/M 23.0x Lower Multiple CVM
Revenue Growth (YoY)
Growth
-19.8% -62.7% Higher Growth PROK
Operating Margin (TTM)
Profitability
-24830.3% 0.0% Higher Margin CVM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-73.4% -252.5% Higher ROE PROK
52-Week Range Position
Momentum
9% ($1–$3) 10% ($1–$8) Stronger Trend CVM
Beta / 30D Volatility
Risk Regime
1.71β · 92% Vol 0.65β · 120% Vol Lower Realized Risk PROK
Unified Institutional Score
Composite Signal
64.1 / 100 (BUY) 56.6 / 100 (HOLD) Higher Composite PROK
Trailing 12M Revenue (USD)
Operating Scale
$775,000 $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($71M Net Cash) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CVM +11.76 pp
PROK: -22.93% · CVM: -11.17%
3M Horizon CVM +25.72 pp
PROK: -25.72% · CVM: +0.0%
6M Horizon CVM +28.78 pp
PROK: -36.34% · CVM: -7.56%
1Y Horizon PROK +18.51 pp
PROK: -57.47% · CVM: -75.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PROK Revenue CVM Revenue PROK Op. Margin CVM Op. Margin Margin Leader
FY2011 N/A $0M N/A -1881.0% CVM
FY2012 N/A $0M N/A -6772.3% CVM
FY2013 N/A $0M N/A -12450.1% CVM
FY2014 N/A $0M N/A -9721.4% CVM
FY2024 $0M N/A -241678.9% N/A PROK
FY2025 $0M N/A -18477.8% N/A PROK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PROK BREAKDOWN
50d in phase · OBV ACCUMULATION
Current IV 364.9%
IV Percentile 42nd %ile
Put/Call OI Skew 0.83x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PROK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PROK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $415.2M market capitalization and -24830.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PROK vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, ProKidney Corp. Class A (PROK) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PROK carries a Unified Composite Score of 64.1/100 (BUY) at $1.02 (N/M Forward P/E, -24830.3% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PROK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.4); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PROK leads the Growth & Scale pillar: PROK posts -19.8% YoY revenue growth and +0.0% YoY earnings growth on $775,000 TTM revenue (100.0% gross margin, -24830.3% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2011 to FY2025), PROK cumulative revenue shifted N/A while CVM shifted N/A. In operating R&D and SG&A reinvestment, PROK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

CVM screens cheaper on headline valuation multiples. PROK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PROK (-73.4% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, PROK carries 364.9% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.71β · 92% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.